- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04284839
Den direkta orala antikoaguleringen mot warfarin efter hjärtkirurgi (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Richard Whitlock, MD, PhD
- Telefonnummer: 40306 905-527-4322
- E-post: richard.whitlock@phri.ca
Studera Kontakt Backup
- Namn: Emilie Belley-Cote, MD, MSc
- Telefonnummer: 40306 905-527-4322
- E-post: emilie.belley-cote@phri.ca
Studieorter
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- Rekrytering
- St Vincent's Hospital Melbourne
-
Kontakt:
- Andrew Newcomb, MD
-
Huvudutredare:
- Andrew Newcomb, MD
-
Parkville, Victoria, Australien, 3050
- Har inte rekryterat ännu
- Royal Melbourne Hospital, University of Melbourne
-
Kontakt:
- Alistair Royse, MD
-
Huvudutredare:
- Alistair Royse, MD
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2C8
- Rekrytering
- University of Alberta Hospital
-
Huvudutredare:
- Steven Meyer, MD
-
Kontakt:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Rekrytering
- University of British Columbia
-
Huvudutredare:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
- Rekrytering
- St. Boniface Hospital
-
Huvudutredare:
- Michael Yamashita, MD
-
Kontakt:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John, New Brunswick, Kanada, E2L4L2
- Aktiv, inte rekryterande
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Rekrytering
- Health Science Centre
-
Huvudutredare:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Kanada, P3E 5J1
- Rekrytering
- Health Sciences North Research Institute
-
Huvudutredare:
- Bindu Bittira, MD
-
Hamilton, Ontario, Kanada, L8L 2X2
- Rekrytering
- Hamilton General Hospital
-
Kontakt:
- Emilie Belley-Cote, MD, MSc
- Telefonnummer: 40306 905-527-4322
- E-post: emilie.belley-cote@phri.ca
-
Toronto, Ontario, Kanada, M5G 2C4
- Rekrytering
- Toronto General Hospital
-
Kontakt:
- Vivek Rao, MD
-
Huvudutredare:
- Vivek Rao, MD
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrytering
- Sunnybrook Hospital
-
Kontakt:
- Stephen Fremes, MD
-
Huvudutredare:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 1C8
- Rekrytering
- Montreal Heart Institute
-
Kontakt:
- Philippe Demers, MD
-
Huvudutredare:
- Philippe Demers, MD
-
Montreal, Quebec, Kanada, H4J1C5
- Rekrytering
- Hôpital Sacré-Coeur de Montréal
-
Huvudutredare:
- Hugues Jeanmart, MD
-
Kontakt:
- Hugues Jeanmart, MD
-
Québec, Quebec, Kanada, G1V 4G5
- Rekrytering
- IUCPQ-ULaval
-
Kontakt:
- Eric Dumont, MD
-
Huvudutredare:
- Eric Dumont, MD
-
-
-
-
-
Bonn, Tyskland, 53127
- Aktiv, inte rekryterande
- University Hospital Bonn Heart Center
-
Essen, Tyskland, 45147
- Har inte rekryterat ännu
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
Kontakt:
- Matthias Thielmann, MD, PhD
-
Huvudutredare:
- Matthias Thielmann, MD, PhD
-
Hamburg, Tyskland, 20246
- Rekrytering
- University Medical Center Hamburg-Eppendorf
-
Kontakt:
- Simon Pecha, MD
-
Huvudutredare:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig, Saxony, Tyskland, 04289
- Aktiv, inte rekryterande
- Heart Center Leipzig
-
-
Thuringia
-
Jena, Thuringia, Tyskland, Germany
- Rekrytering
- University Hospital Jena
-
Kontakt:
- Torsten Doenst, MD, PhD
-
Huvudutredare:
- Torsten Doenst, MD, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Andra namn:
|
|
Placebo-jämförare: Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Major Bleeding
Tidsram: 30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Sammansatt av stroke och systemisk arteriell emboli som inte är centrala nervsystemet efter 30 och 90 dagar.
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Stor blödning
Tidsram: 90 dagar efter randomisering
|
90 dagar efter randomisering
|
|
Pleural eller perikardiell effusion som kräver dränering
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Systemisk arteriell emboli
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Ischemisk stroke
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Djup ventrombos
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Lungemboli
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Längden på postoperativ sjukhusvistelse
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
Dödlighet av alla orsaker
Tidsram: 6 månader efter randomisering
|
6 månader efter randomisering
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Hjärtinfarkt
Tidsram: 30-dagar och 90-dagar efter randomisering
|
30-dagar och 90-dagar efter randomisering
|
|
|
Samband mellan subklinisk ventiltrombos och kliniskt signifikant aortaklafftrombos, stroke eller systemisk emboli
Tidsram: 90 dagar
|
90 dagar
|
|
|
Minor Bleeding
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
Tidsram: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
Tidsram: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
Tidsram: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
Tidsram: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Emilie Belley-Cote, MD, MSc, McMaster University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Patologiska tillstånd, tecken och symtom
- Blödning
- Svavelföreningar
- Organiska kemikalier
- Pyridiner
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Bensimidazol
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Pyraner
- Morfoliner
- Oxaziner
- Tiofener
- Kumarin
- Bensopyraner
- 4-hydroxikoumariner
- Rivaroxaban
- Dabigatran
- Warfarin
- apixaban
- edoxaban
Andra studie-ID-nummer
- DANCE-2020
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .